Companies › CanariaBio
1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Oregovomab Mucin-16 other | MUC16 | Phase 3 | Carcinoma, Ovarian Epithelial; Recurrent Ovarian Cancer; Ovarian Neoplasm Epithelial; Ovarian Cancer by FIGO Stage | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04938583 | Oregovomab | Phase 1 | Ovarian Cancer by FIGO Stage | Oncology | Oct 2025 |
| NCT04498117 | Oregovomab | Phase 3 | Carcinoma, Ovarian Epithelial | Oncology | Dec 2026 |
| NCT05335993 | Oregovomab | Phase 2 | Recurrent Ovarian Cancer | Oncology | Dec 2026 |
| NCT05605535 | Oregovomab | Phase 2 | Ovarian Neoplasm Epithelial | Oncology | May 2027 |
Beijing Biotech Regeneron Pharmaceuticals Whitehawk Therapeutics
Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals FutureGen Biopharmaceutical (Beijing) Epizyme pharmaand
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.